Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Fabry disease
Biotech
BioMarin inks up to $475M deal to challenge Fabry ERT incumbents
BioMarin is paying $70M upfront to license a next-generation Fabry disease therapy, expanding its franchise following the $4.8B Amicus takeover.
Nick Paul Taylor
Oct 29, 2026 10:13am
PTC bets $211M on ‘special opportunity’ to enter Fabry market
Aug 13, 2026 8:15am
UniQure halts mid- to high-dosing for AAV gene therapy
Feb 6, 2026 10:56am
Sanofi GCS inhibitor fails ph. 3 Fabry trial but wins in Gaucher
Feb 2, 2026 5:46am
Cash-strapped Sangamo seeks partner for new gene therapy
Jun 24, 2025 11:53am
4DMT restructures pipeline, extending cash runway through 2028
Jan 10, 2025 2:00pm
